Key result
Icariin reduces LDL cholesterol and atherosclerotic burden in rabbits on a high-cholesterol diet.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for icariin in atherosclerosis; should not yet change clinical practice.
Icariin is a major active component isolated from the traditional Chinese herb Epimedium brevicornum, with a wide range of pharmacological and biological activities. In this paper, we investigated the effects of icariin on hyperlipidemia, and further evaluated whether icariin could improve unfavorable hemorheological parameters, attenuate platelet activation and facilitate the balance between plasmic plasminogen activator inhibitor-1 and tissue-type plasminogen activator activities in rabbits fed a high-cholesterol diet. Icariin reduced the levels of serum total cholesterol and low-density lipoprotein cholesterol, as well as the atherosclerotic burden. In addition, this compound has been found to improve the imbalance between plasmic plasminogen activator inhibitor-1 and tissue-type plasminogen activator activities, reduce platelet adhesiveness and aggregation and modulate unfavorable hemorheological variables in hypercholesterolemia. In conclusion, icariin has lipid-lowering effects and may be used in the treatment and prevention of thrombosis in the atherosclerotic process.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2013) studied Hyperlipidemia and atherosclerosis. Icariin was evaluated on Serum lipid levels, atherosclerotic burden, and hemorheological parameters. Icariin reduced serum total and LDL cholesterol, decreased atherosclerotic burden, and improved hemorheological parameters and platelet activation in rabbits fed a high-cholesterol diet.
Synapse has enriched 10 related papers. Consider them for comparative context: